We believe strong partnerships drive progress towards new medicines for patients
At Ribo Life Science, we combine world-class oligonucleotide discovery capabilities with proven technology to advance siRNA projects within our pipeline globally
We actively seek strategic collaborations within the siRNA field. Also, partnerships to accelerate the advancement of our high-potential assets and co-create value with partners
Ribo signed up with Boehringer Ingelheim to develop new treatments for people with liver diseases.
Ribo granted Qilu Pharmaceutical Co., Ltd. the rights to develop, manufacture and commercialize RBD7022 in Greater China region.